

2024

Catalog

promise  
ADVANCED PROTEOMICS

# SIL-mAbs

# FOR TARGETED LC-MS QUANTIFICATION



The gold standard for robust and reliable quantitative LC-MS workflow

[www.promise-proteomics.com](http://www.promise-proteomics.com) | [contact@promise-proteomics.com](mailto:contact@promise-proteomics.com)

# SIL-MONOCLONAL ANTIBODIES

Promise Proteomics is a pioneer and an expert in the development of mass spectrometry-based quantification methods and in bioproduction of Stable Isotope Labelled monoclonal Antibodies (SIL-mAbs)

## Why use our SIL-mAbs ?

A stable isotope labelled (SIL) form of an analyte protein is widely regarded as the optimal internal standard<sup>1</sup> for absolute quantification of proteins using LC-MS.

SIL-mAbs correct bias (due to losses, incomplete digestion, adsorption, proteolysis...) occurring during the preparation and analytical workflow. With SIL-mAbs, the accuracy and reproducibility of your quantification data is improved.


This product is useful for :

- Bioanalysis pharmacokinetics studies (clinical & nonclinical),
- Research and Discovery/pre-clinical/clinical drug development

## Characteristics

- Full length recombinant monoclonal antibodies
- High isotopic incorporation (>98%) and purity (>95%)
- Labelling on Arg, Lys residues, <sup>13</sup>C <sup>15</sup>N isotope
- Expression systems CHO or HEK

## How to use it ?



Unlike the use of SIL-peptides, Promise's SIL-mAbs are processed along with the target analytes throughout the pre-analytical and LC-MS workflow thus improving robustness and quality of the quantitative data.

1. Todoroki, K. *et al.* (2020, février). Bioanalytical methods for therapeutic monoclonal antibodies and antibody–drug conjugates : A review of recent advances and future perspectives. *Journal of Pharmaceutical and Biomedical Analysis*, 179, 112991. <https://doi.org/10.1016/j.jpba.2019.112991>

# OFF-THE-SHELF PRODUCTS

SIL-mAbs\* are available to support your studies and clinical trials

SIL mAbs	REFERENCE	SIL mAbs	REFERENCE
Abatacept	<a href="#">ORF90261</a>	Infliximab	<a href="#">REX08151</a>
Adalimumab	<a href="#">HUU05211</a>	Inotuzumab	<a href="#">INZ13241</a>
Aflibercept	<a href="#">AFF90271</a>	Ipilimumab	<a href="#">YEH92271</a>
Alemtuzumab	<a href="#">ALZ10131</a>	Ixekizumab	<a href="#">TAZ13261</a>
Avelumab	<a href="#">BAH92571</a>	Mirikizumab	<a href="#">OMZ13191</a>
Belatacept	upon request	Natalizumab	coming soon
Bevacizumab	<a href="#">AVZ10161</a>	Nivolumab	<a href="#">OPH95701</a>
Brentuximab	coming soon	Obinutuzumab	<a href="#">GAH92161</a>
Cemiplimab	coming soon	Ocrelizumab	<a href="#">OCZ10231</a>
Cetuximab	<a href="#">ERX08221</a>	Patritumab	coming soon
Concizumab	<a href="#">COZ13241</a>	Pembrolizumab	<a href="#">KEH95331</a>
Daratumumab	<a href="#">DAU05201</a>	Pertuzumab	<a href="#">PEZ10191</a>
Datopotamab	coming soon	Risankizumab	<a href="#">SKZ10121</a>
Dinutuximab	<a href="#">DIX08251</a>	Rituximab	<a href="#">RIX08221</a>
Dupilumab	<a href="#">DUU08301</a>	Sacituzumab	coming soon
Durvalumab	<a href="#">IMU05501</a>	Secukinumab	<a href="#">COH92201</a>
Eculizumab	<a href="#">SOZ11141</a>	Siltuximab	<a href="#">SYX08151</a>
Emicizumab	<a href="#">HEH95561</a>	Tocilizumab	<a href="#">ACH92241</a>
Epcoritamab	<a href="#">EPZ10171</a>	Trastuzumab	<a href="#">HEZ10231</a>
Etanercept	<a href="#">ENF90251</a>	Ustekinumab	<a href="#">STU05261</a>
Golimumab	<a href="#">SIU05281</a>	Vedolizumab	<a href="#">ENZ10211</a>
Guselkumab	<a href="#">TRU05271</a>		

*\*for Research Use Only*

## Is your SIL-mAb of interest not listed?

For 10 years, Promise Proteomics offers  
**customized bioproduction options.**

Contact us for further information.



 [contact@promise-proteomics.com](mailto:contact@promise-proteomics.com)

# REFERENCES

Peer reviewed publications using our SIL-mAbs

- **University Medical Center Utrecht**

Smeijsters, E. H. E. *et al.* (2023). Optimization of a quantitative Anti-Drug Antibodies against Infliximab assay with the liquid Chromatography-Tandem Mass Spectrometry : A Method Validation Study and Future Perspectives. *Pharmaceutics*, 15(5), 1477. <https://doi.org/10.3390/pharmaceutics15051477>

- **University Medical Center Utrecht**

el Amrani, M. *et al.* (2019). Quantification of neutralizing anti-drug antibodies and their neutralizing capacity using competitive displacement and tandem mass spectrometry : Infliximab as proof of principle. *Journal of Translational Autoimmunity*, 1, 100004. <https://doi.org/10.1016/j.jtauto.2019.100004>

- **Hospices Civils de Lyon**

Millet, A. *et al.* (2019). Determination of Cetuximab in Plasma by Liquid Chromatography–High-Resolution Mass Spectrometry Orbitrap With a Stable Labeled <sup>13</sup>C,<sup>15</sup>N-Cetuximab Internal Standard. *Therapeutic Drug Monitoring*, 41(4), 467-475. <https://doi.org/10.1097/ftd.0000000000000613>

- **University Hospital Grenoble-Alpes**

Jourdil, J. F. *et al.* (2018). Simultaneous Quantification of Adalimumab and Infliximab in Human Plasma by Liquid Chromatography–Tandem Mass Spectrometry. *Therapeutic Drug Monitoring*, 40(4), 417-424. <https://doi.org/10.1097/ftd.0000000000000514>

- **University Hospital Grenoble-Alpes**

Jourdil, J. F. *et al.* (2016). Infliximab quantitation in human plasma by liquid chromatography-tandem mass spectrometry : towards a standardization of the methods ? *Analytical and Bioanalytical Chemistry*, 409(5), 1195-1205. <https://doi.org/10.1007/s00216-016-0045-4>

- **University Medical Center Utrecht**

el Amrani, M. *et al.* (2016). Quantification of active infliximab in human serum with liquid chromatography–tandem mass spectrometry using a tumor necrosis factor alpha -based pre-analytical sample purification and a stable isotopic labeled infliximab bio-similar as internal standard : A target-based, sensitive and cost-effective method. *Journal of Chromatography A*, 1454, 42-48. <https://doi.org/10.1016/j.chroma.2016.05.070>